Despite recent therapeutic advances in cancer treatment, metastasis remains the principal
cause of cancer death. Recent work has uncovered the unique biology of metastasis …

Background Osimertinib is standard-of-care therapy for previously untreated epidermal
growth factor receptor (EGFR) mutation–positive advanced non–small-cell lung cancer …

Non-small-cell lung cancer (NSCLC) represents roughly 85% of lung cancers, with an
incidence that increases yearly across the world. The introduction in clinical practice of …

Background Icotinib has provided survival benefits for patients with advanced, epidermal
growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC). We aimed to …

In this article we summarize our personal non-small cell lung cancer (NSCLC) highlights of
the virtual ASCO 2020 meeting, covering developments in early and advanced-stage …

Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …

Precision medicine in non-small cell lung cancer (NSCLC) is a rapidly evolving area, with
the development of targeted therapies for advanced disease and concomitant molecular …

Epidermal growth factor receptor (EGFR) mutations are the most common oncogenic drivers
in non-small-cell lung cancer (NSCLC). Significant developments have taken place which …

The standard of care (SoC) for medically operable patients with early-stage (stage I–IIIB)
non-small cell lung cancer (NSCLC) is surgery combined with (neo) adjuvant systemic …

Background Treatment of oncogene-addicted non-small cell lung cancer (NSCLC) has been
changed by the advent of tyrosine kinase inhibitors (TKIs). Albeit great benefits are achieved …